Opinion

Video

Evidence-Based Approaches to Intensive Chemotherapy in Secondary AML

Panelists discuss how the NCCN guidelines recommend intensive chemotherapy options, including traditional 7+3 and CPX-351, for newly diagnosed high-risk or secondary AML patients, with treatment selection based on individual patient factors and potential adverse effects.

Video content above is prompted by the following:

  • Please discuss the NCCN guideline recommended first-line treatment options for patients with newly diagnosed high-risk or secondary AML who are potential candidates for intensive chemotherapy induction.
  • Please briefly review the study design & efficacy study of CPX-351 vs. 7+3.
  • How do you monitor and manage potential adverse effects in these patients?
    • Describe management of both 7+3 and CPX-351.
    • How does your approach differ between the two regimens?
Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content